About this trial
Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM).
This is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
Myo-inositol
Dietary supplementPatients would begin taking myoinositol upon recruitment
Myo-inositol placebo
Dietary supplementPatients would begin taking placebo upon recruitment
Treatment groups
Trial outcomes
Primary outcomes
Eligibility
proportion of screened women who were eligible
Glucose levels
Average glucose levels during CGM monitoring period for those enrolled
Sponsors and contacts
Click on the lead sponsor to view all of their trials.